150 related articles for article (PubMed ID: 16310082)
1. Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sézary syndrome.
Kreuter A; Altmeyer P
J Am Acad Dermatol; 2005 Dec; 53(6):1093-5. PubMed ID: 16310082
[No Abstract] [Full Text] [Related]
2. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
3. Acute hyperkeratotic and desquamative reaction in a patient with Sézary syndrome treated with bexarotene.
Bagazgoitia L; Pérez-Carmona L; Ríos L; Muñoz E; Harto A; Jaén P
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):389-90. PubMed ID: 18269619
[No Abstract] [Full Text] [Related]
4. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
5. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
el-Azhary RA; Bouwhuis SA
Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
[TBL] [Abstract][Full Text] [Related]
6. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
[TBL] [Abstract][Full Text] [Related]
7. Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature.
Sanli H; Akay BN; Ozcan M
J Drugs Dermatol; 2010 Aug; 9(8):1014-6. PubMed ID: 20684154
[TBL] [Abstract][Full Text] [Related]
8. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
[TBL] [Abstract][Full Text] [Related]
9. Sézary syndrome associated with granulomatous lesions during treatment with bexarotene.
Ruiz-de-Casas A; Carrizosa-Esquivel A; Herrera-Saval A; Rios-Martín JJ; Camacho F
Br J Dermatol; 2006 Feb; 154(2):372-4. PubMed ID: 16433814
[TBL] [Abstract][Full Text] [Related]
10. Bexarotene combination therapy for patients with Sézary syndrome.
Ranki A
Dermatol Clin; 2008 Jan; 26 Suppl 1():55-7. PubMed ID: 18405189
[No Abstract] [Full Text] [Related]
11. Bexarotene monotherapy for patients with refractory Sézary syndrome.
Staib G; Scharffetter-Kochanek K
Dermatol Clin; 2008 Jan; 26 Suppl 1():61-3. PubMed ID: 18405190
[No Abstract] [Full Text] [Related]
12. CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Gopaluni S; Perzova R; Abbott L; Farah R; Shrimpton A; Hutchison R; Poiesz BJ
Am J Hematol; 2008 Sep; 83(9):744-6. PubMed ID: 18615708
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.
Richardson SK; Newton SB; Bach TL; Budgin JB; Benoit BM; Lin JH; Yoon JS; Wysocka M; Abrams CS; Rook AH
Am J Hematol; 2007 Sep; 82(9):792-7. PubMed ID: 17546636
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
Bagot M
Dermatol Clin; 2008 Jan; 26 Suppl 1():27-9. PubMed ID: 18405184
[No Abstract] [Full Text] [Related]
15. Sustained remission of Sézary syndrome.
Bouwhuis SA; McEvoy MT; Davis MD
Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
[TBL] [Abstract][Full Text] [Related]
16. [Sézary syndrome with rapidly progressing pulmonary lymphoma in a child].
Herman TE
J Radiol; 1992 May; 73(5):331-3. PubMed ID: 1432912
[TBL] [Abstract][Full Text] [Related]
17. [Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma].
Rodriguez Suarez S; Pamies Andreu E; Muñiz Grijalvo O; Garcia Morillo JS
Med Clin (Barc); 2016 Feb; 146(3):117-20. PubMed ID: 26688184
[TBL] [Abstract][Full Text] [Related]
18. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.
McGinnis KS; Ubriani R; Newton S; Junkins-Hopkins JM; Vittorio CC; Kim EJ; Wysocka M; Rook AH
Arch Dermatol; 2005 Sep; 141(9):1176-8. PubMed ID: 16172331
[No Abstract] [Full Text] [Related]
19. [Extracorporeal photopheresis in the therapy of Sézary syndrome].
Marschalkó M; Knobler R; Soós G; Berecz M; Pálóczy K; Rácz I
Orv Hetil; 1993 Jun; 134(23):1253-7. PubMed ID: 8332344
[TBL] [Abstract][Full Text] [Related]
20. Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody).
Osborne GE; Pagliuca A; Ho A; du Vivier AW
Br J Dermatol; 2006 Sep; 155(3):617-20. PubMed ID: 16911291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
